94171-11-6

Basic information

• Product Name: 2-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)ethanone
• Synonyms: 2-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)ethanone;2-(4-Chlorophenyl)-2',4'-dichloroacetophenone
• CAS NO: 94171-11-6
• Molecular Formula: C₁₄H₉Cl₃O
• Molecular Weight: 299.57966
• Mol File: 94171-11-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)ethanone(94171-11-6)
• EPA Substance Registry System: 2-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)ethanone(94171-11-6)

Safety Data

• Hazardous Substances Data: 94171-11-6(Hazardous Substances Data)

Usage

General Description

2-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)ethanone, also known as Diclofenac, is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used as a pain reliever and anti-inflammatory medication. It works by inhibiting the production of prostaglandins, which are chemicals in the body that cause pain and inflammation. Diclofenac is used to treat a variety of conditions, including arthritis, menstrual cramps, and acute pain. It is available in several different forms, including tablets, capsules, and topical gels, and is often prescribed to be taken orally, although it can also be administered topically or intravenously. While generally considered safe and effective, Diclofenac can have some side effects, such as stomach upset, heartburn, and dizziness, and may not be suitable for everyone, especially those with certain medical conditions or allergies.

Upstream product

• 1878-66-6 4-chlorophenylacetic Acid 
• 35112-28-8 methyl 2,4-dichlorobenzoate 
• 25026-34-0 4-chlorophenacetyl chloride 
• 541-73-1 1,3-Dichlorobenzene 
• 1070-89-9 sodium hexamethyldisilazane 
• 622-95-7 4-chlorobenzyl bromide 
• 6574-98-7 2,4-dichlorobenzylnitrile 
• 107732-22-9 2-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-ethanol 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 

Downstream Products

• 94146-96-0 2-Chloro-2-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-ethanone 
• 605670-73-3 2-bromo-2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)ethanone 
• 849813-04-3 3-chloro-2-(4-chlorophenyl)-3-(2,4-dichlorophenyl)-acrylaldehyde 
• 489447-65-6 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)ethane-1,2-dione 
• 611218-31-6 6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile 
• 611218-68-9 2-chloro-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carbonitrile 
• 852315-01-6 6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-(methylamino)pyridine-3-carbonitrile 
• 876293-56-0 1-[5-(4-chloro-phenyl)-6-(2,4-dichloro-phenyl)-2-methylamino-pyridin-3-yl]-ethanone 
• 876293-58-2 6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-(isobutylamino)pyridine-3-carbonitrile 
• 876293-64-0 N-[5-(4-chloro-phenyl)-3-cyano-6-(2,4-dichloro-phenyl)-pyridin-2-yl]-N-methyl-acetamide 
• 876293-60-6 5-(4-chloro-phenyl)-6-(2,4-dichloro-phenyl)-2-(2-methoxy-ethylamino)-nicotinonitrile 
• 852315-04-9 4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-1,8-naphthyridin-2(1H)-one 
• 852315-52-7 N-(6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl)-N-methylpropionamide 
• 876293-59-3 2-benzylamino-5-(4-chloro-phenyl)-6-(2,4-dichloro-phenyl)-nicotinonitrile 

Relevant articles and documents

N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

The subject of the present invention is compounds corresponding to formula (I): Wherein X, R1, R2, R3 and R4 are as described herein. The invention also relates to a method for the preparation and application of said compounds as cannabinoid CB1 receptor antagonists.

N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL)METHYL]AMINE [AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS

The invention concerns compounds of formula (I), wherein X, R1, R2, R3, R4 and R5 are as defined herein. The invention also concerns a method for preparing said compounds and their use as cannabinoid CB1 receptor antagonists.

Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists

Synthesis, SAR, and binding affinities are described for a new class of 1,8-naphthyridinone CB1 receptor specific inverse agonists. Food intake, knockout mouse, and pharmacokinetic evaluation of 14 indicate that this compound is an effective orally active